<DOC>
	<DOCNO>NCT02431676</DOCNO>
	<brief_summary>This prospective , single-center randomize trial three arm , allocation ratio 1:1:1 . The study design efficacy study evaluate effect metformin coach-directed behavioral weight loss versus self-directed weight loss IGF-1 IGF-1 THE IGFBP-III ratio blood level 6 12 month intervention . The coach-directed Behavioral Weight Loss arm web-based remote delivery communication system promote healthy behavioral change . The Metformin arm pharmaceutical intervention oral metformin . This secondary prevention study men woman survive solid malignant tumor</brief_summary>
	<brief_title>Survivorship Promotion In Reducing IGF-1 Trial</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Women men age 18 older Have previously diagnose malignant solid tumor , complete required surgical , and/or chemotherapy and/or radiation curative intent therapy least three month prior enrollment , anticipate treatmentfree life span 12 month longer . Chemoprophylaxis tamoxifen aromatase inhibitor breast cancer woman anti LHRH therapy prostate cancer men permit . Have BMI 25 kg/m2 great weight &lt; =400 lb . Willingness accept randomization three arm Willingness change diet , physical activity , weight Regular access computer reliable Internet connection Ability send receive email Ability complete online form Access phone Willingness provide write informed consent Women breastfeeding , pregnant , plan pregnancy within next year Medicationtreated diabetes Fasting blood glucose &gt; =200 mg/dL , fast blood glucose &gt; =126 &lt; 200 mg/dL HbA1C &gt; =7 % Current prior regular use metformin within past 3 month Uncontrolled concurrent medical condition likely limit compliance study intervention Received chemotherapy ( unless antihormonal therapy ) and/or radiation three month less prior propose intervention date Have prior history lactic acidosis selfreport Prior plan bariatric surgery Have significant renal disease dysfunction define eGFR &lt; 45 Have significant hepatic dysfunction ( AST/ALT â‰¥ 2 x ULN report liver disease ) Selfreported average consumption &gt; 14 alcoholic drink per week Currently enrol plan enroll weight loss program Hemoglobin &lt; 9 g/dl Platelet count &lt; 100 WBC &lt; 2.5 Plans relocate area within one year Use prescription weight loss medication ( ) ( e.g. , lorcaserin , topiramate/phentermine , phentermine , liraglutide , bupropion/naltrexone ) , include label use drug weight loss overthecounter weigh loss medication Orlistat within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>